CTOs on the Move

Aurinia Pharmaceuticals

www.auriniapharma.com

 
Aurinia is a global clinical stage biopharmaceutical company focused on developing and commercializing innovative products to treat identifiable patient populations that are suffering from serious diseases with a high unmet medical need. The company is headquartered in Victoria, BC and focuses its development efforts globally.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.auriniapharma.com
  • 500 W Office Center Drive Suite 400
    Fort Washington, PA USA 19034
  • Phone: 250.708.4272

Executives

Name Title Contact Details
Darin Wilson
Senior Director, Enterprise IT Profile

Funding

Aurinia Pharmaceuticals raised $28.75M on 12/29/2016
Aurinia Pharmaceuticals raised $173.1M on 03/20/2017
Aurinia Pharmaceuticals raised $191.7M on 12/12/2019

Similar Companies

Personal Insurance Administrators

Personal Insurance Administrators is a Agoura Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Silverback Therapeutics

Silverback Therapeutics is charting a new path for treating a range of severe diseases. We are developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness — until now.

Designx Hair Creations

Designx Hair Creations is a Burbank, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Palvella Therapeutics

Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments.

Tyra Biosciences

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. TYRA is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. TYRA is advancing multiple product candidates toward the clinic including its lead product candidate TYRA-300, an FGFR3 inhibitor with an initial focus on patients with bladder cancer, and TYRA-200, an FGFR2 inhibitor with an initial focus on patients with intrahepatic cholangiocarcinoma who have developed drug resistance mutations from existing FGFR inhibitors.